Agency Information Collection Activities; Proposed Collection; Comment Request; FDA Recall Regulations, 38184-38186 [2011-16252]
Download as PDF
38184
Federal Register / Vol. 76, No. 125 / Wednesday, June 29, 2011 / Notices
OMB No.: 0970–0360.
Description: The Office of Adolescent
Health (OAH), Office of the Assistant
Secretary for Health (OASH), U.S.
Department of Health and Human
Services (HHS), is overseeing and
coordinating adolescent pregnancy
prevention evaluation efforts as part of
the Teen Pregnancy Prevention
Initiative. OAH is working
collaboratively with the Office of the
Assistant Secretary for Planning and
Evaluation (ASPE), the Centers for
Disease Control and Prevention (CDC),
and the Administration for Children and
Families (ACF) on adolescent pregnancy
prevention evaluation activities.
The Evaluation of Adolescent
Pregnancy Prevention Approaches
(PPA) is one of these efforts. PPA is a
random assignment evaluation which
will expand available evidence on
effective ways to reduce teen pregnancy.
The evaluation will document and test
a range of pregnancy prevention
approaches in up to eight program sites.
The findings from the evaluation will be
of interest to the general public, to
policy-makers, and to organizations
interested in teen pregnancy prevention.
OAH and ACF are proposing baseline
data collection activity as part of the
PPA evaluation. Baseline data collection
instruments were already approved on
July 26, 2010. The project has worked in
recent months to secure grantees as
evaluation sites, and as part of this effort
the project has undertaken making
revisions to the baseline instrument
with each site. These revisions were
undertaken because each site has
unique features (e.g. target population;
curriculum; objectives) and the baseline
instruments were tailored to take these
features into account. OAH and ACF are
now requesting emergency clearance to
collect data using site-specific
instruments.
Respondents will be asked to answer
carefully selected questions about
demographics and risk and protective
factors related to teen pregnancy.
Information from this data collection
will be used to perform meaningful
analysis to determine significant
program effects.
Respondents: The survey data will be
collected through private, selfadministered questionnaires completed
by study participants, i.e. adolescents
assigned to a select school or
community teen pregnancy prevention
program or a control group. Surveys will
be distributed and collected by trained
professional staff.
ANNUAL BURDEN ESTIMATES
Annualized no.
of respondents
Site/program (and name of baseline instrument)
No. of responses per
respondent
Average burden hours per
response
Total burden
hours
(annual)
Children’s Hospital of Los Angeles/Project AIM ..............................................
Oklahoma Institute of Child Advocacy/Power Through Choices .....................
Engender Health/Gender Matters ....................................................................
Ohio Health/T.O.P.P. .......................................................................................
Live the Life Ministries/WAIT Training .............................................................
Princeton Center for Leadership Training (PCLT)/TeenPEP ..........................
467
360
375
200
533
533
1
1
1
1
1
1
.7
.6
.6
.7
.7
.6
327
216
225
140
373
320
Total ..........................................................................................................
2468
........................
........................
1601
mstockstill on DSK4VPTVN1PROD with NOTICES
Estimated Total Annual Burden
Hours: 1601.
Additional Information:
ACF is requesting that OMB grant a
180 day approval for this information
collection under procedures for
emergency processing by July 1, 2011. A
copy of this information collection, with
applicable supporting documentation,
may be obtained by e-mailing
OPREinfocollection@acf.hhs.gov.
Comments and questions about the
information collection described above
should be directed to the Office of
Information and Regulatory Affairs,
Attn: OMB Desk Officer for ACF, Office
of Management and Budget, Paperwork
Reduction Project, 725 17th Street NW.,
Washington, DC 20503, Fax (202) 395–
6974.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 2011–16290 Filed 6–28–11; 8:45 am]
BILLING CODE 4150–30–P
VerDate Mar<15>2010
17:48 Jun 28, 2011
Jkt 223001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0439]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; FDA Recall
Regulations
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the reporting requirements on FDA
recalls.
SUMMARY:
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
Submit either electronic or
written comments on the collection of
information by August 29, 2011.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Daniel Gittleson, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr. PI50–
400B, Rockville, MD 20850, 301–796–
5156, Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
DATES:
E:\FR\FM\29JNN1.SGM
29JNN1
38185
Federal Register / Vol. 76, No. 125 / Wednesday, June 29, 2011 / Notices
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
FDA Recall Regulations—21 CFR Part 7
(OMB Control Number 0910–0249)—
Extension
Section 701 of the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. 371) and
part 7 (21 CFR part 7), subpart C set
forth the recall regulations (guidelines)
and provide guidance to manufacturers
on recall responsibilities. The
guidelines apply to all FDA regulated
products (i.e., food, including animal
feed; drugs, including animal drugs;
medical devices, including in vitro
diagnostic products; cosmetics;
biological products intended for human
use; and tobacco). These responsibilities
include development of a recall strategy
that requires time by the firm to
determine the actions or procedures
required to manage the recall (§ 7.42);
providing FDA with complete details of
the recall including reason(s) for the
removal or correction, risk evaluation,
quantity produced, distribution
information, firm’s recall strategy, a
copy of any recall communication(s),
and a contact official (§ 7.46); notifying
direct accounts of the recall, providing
guidance regarding further distribution,
giving instructions as to what to do with
the product, providing recipients with a
ready means of reporting to the recalling
firm (§ 7.49); and submitting periodic
status reports so that FDA may assess
the progress of the recall. Status report
information may be determined by,
among other things, evaluation return
reply cards, effectiveness checks and
product returns (§ 7.53); and providing
the opportunity for a firm to request in
writing that FDA terminate the recall
(§ 7.55(b)).
A search of the FDA database was
performed to determine the number of
recalls, and terminations that took place
during fiscal years 2008 to 2010. The
resulting number of total recalls (9,303)
and terminations (2,858) from this
database search were then averaged over
the 3 years, and the resulting per year
average of recalls (3,101) and
terminations (953) are used in
estimating the current annual reporting
burden for this report. FDA estimates
the total annual industry burden to
collect and provide the previous
information to be 443,820 burden hours.
The following is a summary of the
estimated annual burden hours for
recalling firms (manufacturers,
processors, and distributors) to comply
with the voluntary reporting
requirements of FDA’s recall
regulations. Recognizing that there may
be a vast difference in the information
collection and reporting time involved
in different recalls of FDA’s regulated
products, FDA estimates the burden of
this collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of respondents
Number of responses per
respondent
Total annual
responses
Average
burden per
response
Total hours
Recall strategy (§ 7.42) ........................................................
Firm initiated recall and recall communications (§§ 7.46
and 7.49) ..........................................................................
Recall status reports and followup (§ 7.53) .........................
Termination of a recall (§ 7.55(b)) .......................................
3,101
1
3,101
20
62,020
3,101
2,148
953
1
13
1
3,101
27,924
953
30
10
10
93,030
279,240
9,530
Total ..............................................................................
........................
........................
........................
........................
443,820
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
The annual reporting burdens are
explained as follows:
B. Firm Initiated Recall and Recall
Communications
I. Total Annual Reporting
Request firms voluntarily remove or
correct foods and drugs (human or
animal), cosmetics, medical devices,
biologics, and tobacco to immediately
notify the appropriate FDA district
office of such actions. The firm is to
provide complete details of the recall
reason, risk evaluation, quantity
produced, distribution information,
firms’ recall strategy and a contact
official as well as requires firms to
notify their direct accounts of the recall
and to provide recipients with a ready
means of reporting to the recalling firm.
Under these portions of the collection of
mstockstill on DSK4VPTVN1PROD with NOTICES
A. Recall Strategy
Request firms develop a recall strategy
including provision for public warnings
and effectiveness checks. Under this
portion of the collection of information,
the Agency estimates it will receive
3,101 responses annually based on the
average number of recalls over the last
3 fiscal years.
VerDate Mar<15>2010
17:48 Jun 28, 2011
Jkt 223001
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
information, the Agency estimates it
will receive 3,101 responses annually
based on the average number of recalls
over the last 3 fiscal years.
C. Recall Status Reports
Request that recalling firms provide
periodic status reports so FDA can
ascertain the progress of the recall. This
request only applies to firms with active
recalls, and is estimated to be reported
every 2 to 4 weeks. This collection of
information will generate approximately
27,924 responses annually, based on the
average number of recalls over the last
3 fiscal years (3,101), less the average
number of terminations over the last 3
E:\FR\FM\29JNN1.SGM
29JNN1
38186
Federal Register / Vol. 76, No. 125 / Wednesday, June 29, 2011 / Notices
fiscal years (953), multiplied by the
conservative frequency of reporting per
year (13).
D. Termination of a Recall
Provide the firms an opportunity to
request in writing that FDA end the
recall. The Agency estimates it will
receive 953 responses annually based on
the average number of terminations over
the past 3 fiscal years.
II. Hours per Response Estimates
FDA has no information which would
allow it to make a calculated estimate
on the hours per response burden to
FDA regulated firms to conduct recalls.
Variables in the type of products, the
quantity and level of distribution and
the various circumstances of recall
notifications could cause the hours per
response to vary significantly. The best
guesstimate of average burden hours per
response from previous information
collection request reports are utilized
again for the current estimates on
burden hours per response.
Dated: June 23, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–16252 Filed 6–28–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0502]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; National Consumer
Surveys on Understanding the Risks
and Benefits of FDA—Regulated
Medical Products
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by July 29,
2011.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, Fax: 202–
ADDRESSES:
VerDate Mar<15>2010
17:48 Jun 28, 2011
Jkt 223001
395–7285, or e-mailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–New and
title ‘‘National Consumer Surveys on
Understanding the Risks and Benefits of
FDA–Regulated Medical Products.’’
Also include the FDA docket number
found in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
3794.
JonnaLynn.Capezzuto@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
National Consumer Surveys on
Understanding the Risks and Benefits
of FDA–Regulated Medical Products—
(OMB Control Number 0910–NEW)
Risks and benefits are inherent in all
FDA-regulated medical products,
including drugs, biologics, and medical
devices (e.g., pacemakers, implantable
cardiac defibrillators, contact lenses,
infusion pumps). FDA plays a critical
oversight role in managing and
preventing injuries and deaths related to
medical product use. However, the
users of FDA-regulated products are
ultimately the ones who determine
which products are used and how they
are potentially misused. For this reason,
it is critical that the public understand
the risks and benefits of FDA-regulated
medical products to a degree that allows
them to make rational decisions about
product use.
FDA’s responsibility includes
communicating about medical products.
This encompasses communications that
FDA generates and those it oversees
through regulation of product
manufacturers’ and distributors’
communications. Activities include, but
are not limited to, recall notices,
warnings, public health advisories and
notifications, press releases, and
information made available on its Web
site. FDA also regulates
communications drafted and
disseminated by manufacturers and
distributors of many medical products,
including all the communications
(advertising and labeling) about
prescription drugs, biologics, and
restricted medical devices, and a subset
of communications (omitting
advertising) about nonprescription
drugs and other medical devices. In
order to conduct educational and public
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
information programs relating to these
responsibilities, as authorized by
section 1003(d)(2)(D) of the Federal
Food Drug and Cosmetic Act (21 U.S.C.
393(d)(2)(D)), it is beneficial for FDA to
conduct research and studies relating to
health information as authorized by
section 1701(a)(4) of the Public Health
Service Act (42 U.S.C. 300u(a)(4)).
In conducting such research, FDA
will employ nationally representative
surveys of consumers to assess whether
the information being disseminated by
both the Agency and the entities it
regulates is appropriately reaching
targeted audiences in an understandable
fashion. Specifically, the surveys will
assess public understanding about the
benefits and risks of medical products
and FDA’s role in regulating these
products. The surveys will assess
behaviors and beliefs related to the use
of medical products, when consumers
desire emerging risk information, the
likelihood of reporting serious side
effects that might be associated with
medical product use, perceptions of the
credibility of FDA and other potential
sources of risk and benefit information,
and satisfaction with FDA’s
communications-related performance.
Parallel surveys of 1,500
noninstitutionalized U.S. adults will be
administered. One survey of 1,500
subjects will be a telephone survey, and
the second survey of another 1,500
subjects will be conducted with
members from an Internet panel. Both
survey samples will be constructed to be
representative of the U.S. population,
and both will take approximately 15
minutes to administer. Results from
each survey will be compared to
provide insight into the best
methodology for future studies.
The information collected will be
used by FDA in the development of
more effective risk communication
strategies and messages. The surveys
will provide FDA insight as to how well
the public understands and incorporates
risk/benefit information into their belief
structures, and how well the public
understands the context within which
FDA makes decisions on medical
product recalls and warnings. Using this
information, the Agency will more
effectively design messages and select
formats and distribution channels that
have the greatest potential to influence
the target audience’s attitudes and
behavior in a favorable way. Frequency
of Response: On occasion. Affected
Public: Individuals or households; Type
of Respondents: Members of the public.
In the Federal Register of October 5,
2010 (75 FR 61490), FDA published a
60-day notice requesting public
comment on the proposed collection of
E:\FR\FM\29JNN1.SGM
29JNN1
Agencies
[Federal Register Volume 76, Number 125 (Wednesday, June 29, 2011)]
[Notices]
[Pages 38184-38186]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-16252]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0439]
Agency Information Collection Activities; Proposed Collection;
Comment Request; FDA Recall Regulations
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on the reporting requirements on
FDA recalls.
DATES: Submit either electronic or written comments on the collection
of information by August 29, 2011.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.
PI50-400B, Rockville, MD 20850, 301-796-5156,
Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
[[Page 38185]]
or requirements that members of the public submit reports, keep
records, or provide information to a third party. Section 3506(c)(2)(A)
of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to
provide a 60-day notice in the Federal Register concerning each
proposed collection of information, including each proposed extension
of an existing collection of information, before submitting the
collection to OMB for approval. To comply with this requirement, FDA is
publishing notice of the proposed collection of information set forth
in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
FDA Recall Regulations--21 CFR Part 7 (OMB Control Number 0910-0249)--
Extension
Section 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
371) and part 7 (21 CFR part 7), subpart C set forth the recall
regulations (guidelines) and provide guidance to manufacturers on
recall responsibilities. The guidelines apply to all FDA regulated
products (i.e., food, including animal feed; drugs, including animal
drugs; medical devices, including in vitro diagnostic products;
cosmetics; biological products intended for human use; and tobacco).
These responsibilities include development of a recall strategy that
requires time by the firm to determine the actions or procedures
required to manage the recall (Sec. 7.42); providing FDA with complete
details of the recall including reason(s) for the removal or
correction, risk evaluation, quantity produced, distribution
information, firm's recall strategy, a copy of any recall
communication(s), and a contact official (Sec. 7.46); notifying direct
accounts of the recall, providing guidance regarding further
distribution, giving instructions as to what to do with the product,
providing recipients with a ready means of reporting to the recalling
firm (Sec. 7.49); and submitting periodic status reports so that FDA
may assess the progress of the recall. Status report information may be
determined by, among other things, evaluation return reply cards,
effectiveness checks and product returns (Sec. 7.53); and providing
the opportunity for a firm to request in writing that FDA terminate the
recall (Sec. 7.55(b)).
A search of the FDA database was performed to determine the number
of recalls, and terminations that took place during fiscal years 2008
to 2010. The resulting number of total recalls (9,303) and terminations
(2,858) from this database search were then averaged over the 3 years,
and the resulting per year average of recalls (3,101) and terminations
(953) are used in estimating the current annual reporting burden for
this report. FDA estimates the total annual industry burden to collect
and provide the previous information to be 443,820 burden hours.
The following is a summary of the estimated annual burden hours for
recalling firms (manufacturers, processors, and distributors) to comply
with the voluntary reporting requirements of FDA's recall regulations.
Recognizing that there may be a vast difference in the information
collection and reporting time involved in different recalls of FDA's
regulated products, FDA estimates the burden of this collection of
information as follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of Average
Number of responses per Total annual burden per Total hours
respondents respondent responses response
----------------------------------------------------------------------------------------------------------------
Recall strategy (Sec. 7.42)... 3,101 1 3,101 20 62,020
Firm initiated recall and recall 3,101 1 3,101 30 93,030
communications (Sec. Sec.
7.46 and 7.49).................
Recall status reports and 2,148 13 27,924 10 279,240
followup (Sec. 7.53).........
Termination of a recall (Sec. 953 1 953 10 9,530
7.55(b)).......................
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 443,820
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
The annual reporting burdens are explained as follows:
I. Total Annual Reporting
A. Recall Strategy
Request firms develop a recall strategy including provision for
public warnings and effectiveness checks. Under this portion of the
collection of information, the Agency estimates it will receive 3,101
responses annually based on the average number of recalls over the last
3 fiscal years.
B. Firm Initiated Recall and Recall Communications
Request firms voluntarily remove or correct foods and drugs (human
or animal), cosmetics, medical devices, biologics, and tobacco to
immediately notify the appropriate FDA district office of such actions.
The firm is to provide complete details of the recall reason, risk
evaluation, quantity produced, distribution information, firms' recall
strategy and a contact official as well as requires firms to notify
their direct accounts of the recall and to provide recipients with a
ready means of reporting to the recalling firm. Under these portions of
the collection of information, the Agency estimates it will receive
3,101 responses annually based on the average number of recalls over
the last 3 fiscal years.
C. Recall Status Reports
Request that recalling firms provide periodic status reports so FDA
can ascertain the progress of the recall. This request only applies to
firms with active recalls, and is estimated to be reported every 2 to 4
weeks. This collection of information will generate approximately
27,924 responses annually, based on the average number of recalls over
the last 3 fiscal years (3,101), less the average number of
terminations over the last 3
[[Page 38186]]
fiscal years (953), multiplied by the conservative frequency of
reporting per year (13).
D. Termination of a Recall
Provide the firms an opportunity to request in writing that FDA end
the recall. The Agency estimates it will receive 953 responses annually
based on the average number of terminations over the past 3 fiscal
years.
II. Hours per Response Estimates
FDA has no information which would allow it to make a calculated
estimate on the hours per response burden to FDA regulated firms to
conduct recalls. Variables in the type of products, the quantity and
level of distribution and the various circumstances of recall
notifications could cause the hours per response to vary significantly.
The best guesstimate of average burden hours per response from previous
information collection request reports are utilized again for the
current estimates on burden hours per response.
Dated: June 23, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-16252 Filed 6-28-11; 8:45 am]
BILLING CODE 4160-01-P